Premium
Pharmacology and Clinical Efficacy of Ranitidine, A New H 2 ‐Receptor Antagonist
Author(s) -
Helman Colin A.,
Tim Leonard Ou
Publication year - 1983
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1983.tb03248.x
Subject(s) - cimetidine , ranitidine , pharmacology , antagonist , histamine h2 receptor , medicine , histamine , potency , receptor antagonist , gastric acid , chemistry , receptor , stomach , in vitro , biochemistry
Ranitidine is a new histamine H 2 ‐receptor antagonist that includes a furan ring structure, whereas other H 2 ‐receptor antagonists include an imidazole ring. It is more potent than cimetidine in inhibiting gastric acid secretion and lacks cimetidine's anti‐androgenic and hepatic microsomal enzyme inhibiting effects. In the recommended dosage of 150 mg twice daily, ranitidine is as effective as cimetidine in healing duodenal and gastric ulcers and has the advantages of less frequent dosing and fewer side effects. Ranitidine appears to be the drug of choice in the treatment of the Zollinger‐Ellison syndrome because of its increased potency and lesser effect on endocrine function compared to cimetidine.